Wockhardt USA LLC

Wockhardt's Zaynich, a Phase III antibiotic, cleared a chronic bile duct infection, enabling a liver transplant and resuming chemotherapy for a 73-year-old patient. The drug has benefited 45 patients with life-threatening Gram-negative infections under compassionate use in the US. Zaynich, a 'β-lactam enhancer', is also being evaluated for complicated urinary tract infections.

Wockhardt Ltd. shares rose 10% after announcing Zaynich (WCK 5222) successfully treated a US cancer patient, neutralizing resistant pathogens. The drug nears Phase III study completion for global registration. The company focuses on antibacterial drugs for untreatable superbugs, with 45 patients benefiting so far.

India's Nafithromycin, a new Macrolide antibiotic, aims to combat antimicrobial resistance, particularly in treating Community-Acquired Bacterial Pneumonia. Developed with significant investment and clinical trials, it offers improved efficacy and shorter treatment times. The government supports AMR initiatives, including the National Action Plan on AMR, to enhance surveillance and public awareness.

Indian scientists developed Nafithromycin, an indigenous antibiotic targeting Community-Acquired Bacterial Pneumonia (CABP), crucial in combating antimicrobial resistance (AMR). Marketed as 'Miqnaf', it treats drug-resistant bacteria, particularly affecting vulnerable populations. Nafithromycin, 10 times more effective than current treatments, offers a three-day regimen, improving patient compliance and safety. Experts emphasize the need for rational antibiotic use to prevent resistance.

India developed Nafithromycin, its first indigenous Macrolide antibiotic, after 30 years of research, to combat antimicrobial resistance (AMR). Nafithromycin, marketed as 'Miqnaf,' targets Community-Acquired Bacterial Pneumonia (CABP) and is ten times more effective than current treatments, offering a three-day treatment regimen. The drug, developed with ₹500 crores, awaits final approval from the Central Drugs Standard Control Organization (CDSCO). India also combats AMR through surveillance, awareness, and international collaboration initiatives.

India's pharmaceutical sector introduces new antibiotics like Enmetazobactam and Zaynich to combat superbugs, amid rising antimicrobial resistance. Despite innovations, misuse and overprescription of antibiotics persist, necessitating holistic solutions and global cooperation.

Nafithromycin (Miqnaf) developed by Wockhardt with BIRAC support targets CABP, addressing 2M+ annual deaths. It combats AMR, offers 10x efficacy over azithromycin, broad-spectrum action, minimal side effects, and is the first in its class worldwide in 30 years. Extensive clinical trials and ₹500 crore investment underscore its reliability. Awaiting CDSCO approval, it promises 96.7% cure rate for drug-resistant pneumonia and will be integrated into Ayushman Bharat, tackling the AMR crisis globally.

India's new drugs aim to combat antibiotic-resistant superbugs, with Enmetazobactam and Zaynich showing promise. Antibiotic resistance caused 1.14 million deaths globally in 2021, with India facing significant challenges. Innovative drugs and better prescription practices are crucial to address this growing threat.

The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.

DelveInsight's report on Complicated Urinary Tract Infection (UTI) clinical trials highlights 12+ companies developing 12+ pipeline drugs, with therapies in various stages of development, including Phase III. Key companies include Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals, Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, and MerLion Pharmaceuticals.